Interestingly, in ovarian cancer patients, the PARP1 p.R591C mutation (c.1771C>T) showed de novo resistance to olaparib, showing clinical evidence of PARP mutations as another mechanism of PARPi resistance [48]. This evidence concerns the gene PARP1 and ovarian carcinoma.